Evaluation of a Biologic For Lupus
Powered by
Information About this Study
This is a phase 2 randomized, open-label, active-controlled study evaluating the safety and efficacy of a biologic in people with Lupus.
The primary objective of this study is to evaluate the efficacy of a biologic in people with systemic lupus erythematosus (SLE) at least 24 weeks prior to screening.
Who Can Participate
-
18 years and older
Participant must be diagnosed with systemic lupus erythematosus (SLE) at least 24 weeks prior to screening
Participant has a modified Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) score ≥ 6 at screening
-
History of or positive test result for human immunodeficiency virus (HIV).
Current hepatitis C infection (defined as positive hepatitis C virus (HCV) antibody and detectable HCV ribonucleic acid [RNA]).
Current hepatitis B infection (defined as positive for hepatitis B surface antigen (HBsAg) and/or total hepatitis B core antibody [anti-HBc]).
History of severe herpes infection.
Why Should I Participate in this Study?
The Lupus Foundation of America estimates that 1.5 million Americans, and at least five million people worldwide, have a form of lupus.
One of the most effective ways to improve the lives of people with lupus is through research. Research holds the keys to discovering what causes lupus, to creating better treatments, and ultimately, to finding a cure.
About the Study App
This study is being conducted using the Health Storylines™ app which can be accessed through your smartphone, mobile device, laptop, personal computer, tablet, or web browser.
How to Participate
To register your interest in participating, please download the Health Storylines™ app using the links underneath to sign up for this study.
You can also scan the following QR code to access the mobile version.
Thank you for your consideration of this important research study.